Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 427 |
Synonyms | |
Therapy Description |
AMG 427 is a bi-specific T-cell engager (BiTE) antibody that binds to FLT3 and CD3, which activates cytotoxic T-lymphocytes against tumor cells expressing FLT3, potentially resulting in increased death of FLT3-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 427 | AMG-427|AMG427|BiTE Antibody AMG 427|Anti-FLT3 x Anti-CD3 BiTE AMG 427 | CD3 Antibody 99 FLT3 Antibody 5 | AMG 427 is a bi-specific T-cell engager (BiTE) antibody that binds to FLT3 and CD3, which activates cytotoxic T-lymphocytes against tumor cells expressing FLT3, potentially resulting in increased death of FLT3-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03541369 | Phase I | AMG 427 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528) | Terminated | USA | DEU | CAN | AUS | 2 |